Trial Profile
A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Breast cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 23 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.